The bacterium B. cereus had so far been considered to be exclusively endospore-forming. In response to harsh conditions, the bacteria form protective endospores enabling them to remain dormant for extended periods. When conditions are more favorable, the endospores reactivate to become fully functioning bacteria.
This is a light micrograph of B. cereus in a small colony variant. Courtesy of Markus Kranzler/Vetmeduni Vienna
The bacterium B. cereus had so far been considered to be exclusively endospore-forming. In response to harsh conditions, the bacteria form protective endospores enabling them to remain dormant for extended periods. When conditions are more favorable, the endospores reactivate to become fully functioning bacteria.
Elrike Frenzel, Markus Kranzler and Monika Ehling-Schulz of the Institute of Microbiology at the University of Veterinary Medicine Vienna have now shown for the first time that B. cereus has an alternative lifestyle in the form of so called small colony variants (SCVs). In B. cereus these SCVs form in response to exposure with aminoglycoside antibiotics. SCVs grow slower than the original form of B. cereus. They have an altered metabolism and are resistant to those antibiotics which triggered this state, namely aminoglycosides.
"The bacterium protects itself against the harmful effects of the antibiotics by forming these Small Colony Variants. But B. cereus is usually treated with exactly those antibiotics which induce the SCV state. If an antibiotic triggers the formation of SCVs, it also triggers resistance," first author Frenzel explains.
The mechanism discovered by Frenzel, Kranzler and Ehling-Schulz is of enormous significance in clinical practice. Traditional diagnostic methods are based on the identification of metabolic features of B. cereus. These tests will not detect SCVs, however, as they have a slower, altered metabolism. This may result in incorrect antibiotic therapies or even failed diagnoses. Study author Frenzel sees molecular-based diagnostics as the only way to diagnose this form of B. cereus.
Treating B. cereus infections using only aminoglycoside antibiotics could bear the risk of a prolonged infection. SCVs grow more slowly, but they still produce toxins that are harmful to the body. "In this case, a combination therapy with other antibiotic groups is advisable," Frenzel recommends.
One species of bacteria that has been known for years to be a multiresistant hospital pathogen and which poses a life-threatening risk for immunocompromised individuals in particular is Staphylococcus aureus. Those bacteria also form SCVs, but unlike B. cereus they are capable of reverting to its original state. For B. cereus, the adaptation to a small colony variant appears to be final. "We believe that the SCV formation in B. cereus functions differently than in S. aureus," says study author Ehling-Schulz.
"The ability to form SCVs appears to be of environmental significance for the bacteria," Frenzel believes. "This alternative lifestyle allows the bacteria to avoid threatening stress factors such as antibiotic exposure. B. cereus are soil-dwelling, and other microorganism in the soil produce antibiotics. Here, too, the formation of SCVs would be an advantage for the bacteria."
Source: University of Veterinary Medicine -- Vienna
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.